Tweet

Imulan BioTherapeutics Licenses New Immune Modulator

Author: Imulan BioTherapeutics
Posted: Sunday 7th January, 2007. 00:00:00

SCOTTSDALE, Ariz. – (January 7th, 2007)   Imulan BioTherapeutics, LLC (Imulan), a privately-held bioscience company, announced the worldwide licensing of a novel immune modulating vaccine technology for animal health applications.

Dr. Craig Woods, CEO of Imulan, stated, “The vaccine proposes to manage a number of conditions, including allergic reactions, infections, cancer and autoimmune disorders. Studies indicate the vaccine helps to restore normal T-helper cell activity and cytokine balance. The potential applications in livestock and companion animals may provide veterinarians a much needed tool to manage a significant number of clinically challenging conditions.“

Founded in 2004, Imulan has initiated the development of several platform technologies, including the ImSAIDs™, for animal health.  Imulan is focused on developing unique immune regulating compounds with predictable effects.  For more information about Imulan, please visit www.imulan.com.

This article has been viewed 3236 times.

 

Comments about this article